Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cyclacel
Biotech
Cash-strapped Cyclacel cuts costs while searching for salvation
Cyclacel will begin to slash its operating costs as the cancer-focused biotech explores "strategic alternatives on an expedited basis."
James Waldron
Dec 6, 2024 9:11am
Ex-Eisai leader to be new NextPoint CEO—Chutes & Ladders
Feb 2, 2024 9:30am
Cyclacel passes phase 3 leukemia drug rights back to Daiichi
Nov 10, 2022 10:05am
Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor
Apr 16, 2018 9:38am
Cyclacel AML drug fails phase 3, wiping 30% off stock
Feb 23, 2017 8:37am
